

Ultra-Ostivone™ Nutritional support for bone health

DESCRIPTION

Ultra-Ostivone™ from Douglas Laboratories is a dietary supplement with highly absorbable calcium, vitamin D, and ipriflavone that provides outstanding nutritional support for bone structure and function.

FUNCTIONS

The adult human body contains approximately 1,200 g of calcium, about 99% of which is present in the skeleton. Bone is constantly turning over, a continuous process of formation and resorption. In children and adolescents, the rate of formation of bone mineral predominates over the rate of resorption. Once one reaches peak bone mass, sometime between the age of 20 and 30, bone formation slows down and bone resorption begins to prevail over bone formation, beginning the cycle of progressive, age-associated bone demineralization. Therefore, in normal aging, there is a gradual loss of bone. The condition of reduced bone mineral density can increase risk of fractures and affects a large proportion of the elderly in developed countries. Caucasian and Asian women typically have low peak bone densities, and therefore, are at the greatest risk of fractures in later life. It is generally accepted that obtaining enough dietary calcium throughout life can significantly decrease the risk of fractures due to reduced bone density. Among other factors, such as regular exercise, gender and race, calcium supplementation during childhood and adolescence appears to be a prerequisite for maintaining adequate bone density later in life. But even the elderly can benefit significantly from supplementation with dietary calcium. In women, bone loss is generally accelerated following menopause. The decline in estrogen levels associated with menopause appears to put women at increased risk for declining bone density and associated fractures. Ipriflavone, derived from naturally occurring isoflavones, promotes bone density by inhibiting bone resorption. Numerous studies of postmenopausal women and individuals whose bones are showing signs of demineralization have investigated the benefits of ipriflavone on bone health. Laboratory and clinical studies have documented ipriflavone's positive effect on bone density. Experts agree that ipriflavone appears to directly inhibit osteoclast activity, thereby decreasing bone resorption. Osteoclasts and osteoblasts are two primary types of bone cells. Osteoblasts, the more exterior cells, are responsible for bone mineralization. Osteoclasts, found beneath the osteoblasts, are responsible for bone resorption. When calcium levels in the blood drop, the osteoblasts change shape, allowing the osteoclasts to become exposed and release calcium from the bones to the rest of the body. Scientists suspect ipriflavone may also stimulate osteoblast activity. Since osteoblasts are responsible for laying down new bone, an increase in osteoblast activity would result in increased bone mineralization. This suggests ipriflavone may not only inhibit the breakdown of existing bone, but also encourage the formation of new bone. Ipriflavone, together with adequate calcium and vitamin D, a key regulatory hormone for calcium and bone metabolism, offers non-estrogenic protection against excessive bone resorption. Unlike other well-known isoflavones, such as genistein found in soy foods, ipriflavone does not have estrogenic activity. Ipriflavone can be safely used in conjunction with natural phytoestrogens or with hormone replacement therapy. Furthermore, ipriflavone provides a positive effect on bone health in women for whom hormone therapies are contraindicated.

INDICATIONS

Ultra-Ostivone™ may be a useful dietary supplement for those who wish to support the healthy functioning of their bone structure.

FORMULA (#83916)

Each Vcaps™ Vegetarian Capsule Contains:

Vitamin D	50 I.U.
Calcium (from Calcium Citrate/Carbonate Complex)	150 mg
Ostivone™ (Ipriflavone)	300 mg

Ostivone is a trademark of TSI

Ultra-Ostivone™

Nutritional support for bone health

SUGGESTED USE

Adults take 1 capsule 2 times daily or as directed by physician.

SIDE EFFECTS

No adverse side effects have been reported.

STORAGE

Store in a cool, dry place, away from direct light. Keep out of reach of children.

REFERENCES

- Adami S, Bufalino L, Cervetti R, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Serni U, Vecchiet L, Passeri M. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. *Osteoporos Int* 1997;7:119-25.
- Agnusdei D, Adami S, Cervetti R, Crepaldi G, Di Munno O, Fantasia L, Isaia GC, Letizia G, Ortolani S, Passeri M, et al. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. *Bone Miner* 1992;19 Suppl 1:S43-8.
- Bendich A, Leader S, Muhuri P. Supplemental calcium for the prevention of hip fracture: potential health-economic benefits. *Clin Ther* 1999;21:1058-72.
- Benvenuti S, Petilli M, Frediani U, Tanini A, Fiorelli G, Bianchi S, Bernabei PA, Albanese C, Brandi ML. Binding and bioeffects of Ipriflavone on a human preosteoclastic cell line. *Biochem Biophys Res Commun* 1994;201:1084-9.
- Bronner F. Calcium and osteoporosis. *Am J Clin Nutr* 1994;60:831-6.
- Bronner F, Pansu D. Nutritional aspects of calcium absorption. *J Nutr* 1999;129:9-12.
- Castelo-Branco C. Management of osteoporosis. An overview. *Drugs Aging* 1998;12:25-32.
- Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. *Calcif Tissue Int* 1994;55:356-62.
- Civitelli R. In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics. *Calcif Tissue Int* 1997;61:S12-4.
- Civitelli R, Abbasi-Jarhomi SH, Halstead LR, Dimarogonas A. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. *Calcif Tissue Int* 1995;56:215-9.
- de Aloysio D, Gambacciani M, Altieri P, Ciaponi M, Ventura V, Mura M, Genazzani AR, Bottiglioni F. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. *Gynecol Endocrinol* 1997;11:289-93.
- Gambacciani M, Cappagli B, Piaggese L, Ciaponi M, Genazzani AR. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. *Calcif Tissue Int* 1997;61:S15-8.
- Gambacciani M, Ciaponi M, Cappagli B, Piaggese L, Genazzani AR. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. *Maturitas* 1997;28:75-81.
- Gennari C, Adami S, Agnusdei D, Bufalino L, Cervetti R, Crepaldi G, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani S, Passeri M, Serni U, Vecchiet L. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. *Calcif Tissue Int* 1997;61:S19-22.
- Gennari C, Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani S, Bufalino L, Passeri M. Effect of ipriflavone--a synthetic derivative of natural isoflavones-- on bone mass loss in the early years after menopause. *Menopause* 1998;5:9-15.
- Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. *Clin Ther* 1999;21:1025-44.
- Nardo F, Scrofani V, Costa G, Bellanca S, Petrovec MM, Clemenza F, Licciardello S. [Therapeutic protocols compared in the treatment of postmenopausal osteoporotic disease]. *Minerva Ginecol* 1994;46:305-15.

Ultra-Ostivone™ Nutritional support for bone health

Nozaki M, Hashimoto K, Inoue Y, Ogata R, Okuma A, Nakano H. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. *Int J Gynaecol Obstet* 1998;62:69-75.

O'Brien KO. Combined calcium and vitamin D supplementation reduces bone loss and fracture incidence in older men and women. *Nutr Rev* 1998;56:148-50.

Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. *Horm Res* 1999;51:178-83.

Petilli M, Fiorelli G, Benvenuti S, Frediani U, Gori F, Brandi ML. Interactions between ipriflavone and the estrogen receptor. *Calcif Tissue Int* 1995;56:160-5.

Reid IR. The roles of calcium and vitamin D in the prevention of osteoporosis. *Endocrinol Metab Clin North Am* 1998;27:389-98.

For more information on Ultra-Ostivone™ visit douglaslabs.com

† These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

Manufactured by
Douglas Laboratories
600 Boyce Road
Pittsburgh, PA 15205
800-245-4440
douglaslabs.com



**You trust Douglas Laboratories.
Your patients trust you.**

© 2012 Douglas Laboratories. All Rights Reserved